thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    broken image
    broken image

    seek and you will find

    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    • …  
      • Home
      • Technology
      • Products 
        • Products Overview
        • SeekInCare
        • SeekInCure
        • SeekInClarity
        • OncoSeek
        • LeukoPrint
      • Publication 
        • Research
        • Others
      • Newsroom
      • Product & Service Inquiry
      broken image
      • SeekInCureTM

        The first-in-class blood-based pan-cancer recurrence monitoring test

        broken image

        SeekInCureTM is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .

        broken image
        Add paragraph text here.
      • A panoramic view of cancer genomic landscape

        cfDNA detection via NGS drawing the view of cancer genomic landscape

        Cutting-edge multivariate algorithm

        Genomics combined with proteomics,capturing the signal of cancer recurrence

        Multidimensional fingerprint

        CNA, Fragmentation and protein markers discovering the early cancer recurrence

        Big data and Artificial intelligence

        CRI model based on machine learning evaluating the risk of cancer recurrence precisely

      • broken image
      • Specifications

        ◉ Indicated subjects: post-surgery cancer patients

        ◉ Sample requirement: 8ml peripheral blood

        ◉ Result readout: CRI (cancer recurrence index)

        ◉ Turnaround time (TAT): 10 working days

        Sampling time

        broken image
      • How it works

        broken image

        Pre-test inquiry

         

        broken image

        Informed consent 

        broken image

        Blood-draw

        broken image

        Testing

        broken image

        Analyzing + Interpretation

         

        broken image

        Reporting

         

      Navigation

      Technology   

      SeekInCare

      SeeInCure

      SeekInClarity

      OncoSeek

      Research

      Contact Us

      10320 Camino Santa Fe, Suite G

      San Diego, CA 92121

      United States

      info@seekincancer.com

      © 2024 SeekIn Inc.

      All Rights Reserved.

      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More